Study to Evaluate the Safety and Efficacy of Emtricitabine and Tenofovir Alafenamide (F/TAF) Fixed-Dose Combination Once Daily for Pre-Exposure Prophylaxis in Men and Transgender Women Who Have Sex With Men and Are At Risk of HIV-1 Infection (opens ClinicalTrials.gov)
- Sponsor
- Gilead Sciences
- Enrolment
- 5,399
- Started
- 2016-09-02
- Last update
- 2026-09-08
Conditions: Pre-Exposure Prophylaxis of HIV-1 Infection
Interventions: F/TAF, F/TDF, F/TAF Placebo, F/TDF Placebo